Introduction Dolutegravir (DTG) , an HIV integrase inhibitor, is metabolized mainly by glucuronidation via UDPglucuronosyltransferase 1A1 (UGT1A1) (Fig. 1) . Several UGT1A1 polymorphisms have been correlated with the UGT1A1 expression level and enzymatic activity. Allele frequencies of UGT1A1*28 vary with race, and are relatively high in Caucasian and African-American Populations 1) . Allele frequencies of UGT1A1*6 also vary with race, and are low in Western populations, but high in Asian populations 2) .
We compared the effects of the two polymorphic alleles, UGT1A1*6 and UGT1A1*28, on plasma DTG concentrations in Japanese HIV-1-infected patients.
The trough concentrations of plasma DTG were measured in 69 Japanese HIV-1 patients who were taking DTG at Osaka National Hospital, and UGT1A1 genetic screening (*6 and *28) was performed. UGT1A1 was genotyped using the sequencing method 4) . Plasma was sampled immediately before DTG administration, and plasma DTG concentrations were determined using liquid chromatography-mass spectrometry 5) . This study was reviewed and approved by the Institutional Review Board of the National Hospital Organization Osaka National Hospital (approval number: 0838). 
The frequencies of UGT1A1*6 and UGT1A1*28 were 23% and 13%, respectively. The trough concentrations of plasma DTG were significantly higher in patients homozygous for UGT1A1*6 (n = 7, median: 1.4 µg/mL) than in patients carrying the normal allele (n = 32, median: 0.89 µg/mL; p = 0.011). The trough concentrations of plasma DTG in patients homozygous for UGT1A1*28 (n = 3, median: 1.2 µg/mL), compound heterozygous for UGT1A1*6 and UGT1A1*28 (n = 2, 0.98 and 1.2 µg/mL, respectively), or heterozygous for UGT1A1*6 and UGT1A1*28 (n = 15 and 10, median: 1.1 and 1.0 µg/mL, respectively) were not significantly different from those in patients homozygous for the normal allele.
Conclusions
The trough concentrations of plasma DTG were significantly higher in patients homozygous for UGT1A1*6 than in those with the normal allele. This suggests that the presence of UGT1A1*6 influences plasma DTG concentrations. -/-−/*28 *28/*28 *6/*6 -/*6 Trough concentration of plasma dolutegravir (µg/mL) UGT1A1 genotype *6/*28
